Picture of Ayala Pharmaceuticals logo

ADXS Ayala Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m-39.78%
3m-11.64%
6m-42.58%
1yr-67.8%
Volume Change (%)
10d/3m-59.99%
Price vs... (%)
52w High-69.23%
50d MA-17.78%
200d MA-31.88%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equity-254.99%
Operating Margin-248761.54%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Oct 202331st Oct 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Ayala Pharmaceuticals EPS forecast chart

Profile Summary

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The Company's lead candidates under development are the oral gamma secretase inhibitor, AL102, for desmoid tumors, and aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). The Company's product candidates, AL101 and AL102, are being developed as potent, selective, small molecule gamma secretase inhibitors (GSIs). AL101 and AL102 targets the aberrant activation of the Notch pathway using gamma secretase inhibitors. The product candidates have the potential to transform treatment outcomes for patients suffering from rare and aggressive cancers. The Company's Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine.

Directors

Last Annual
October 31st, 2022
Last Interim
September 30th, 2023
Incorporated
February 28th, 2002
Public Since
July 28th, 2005
No. of Shareholders
80
No. of Employees
14
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
42,633,400

ADXS Share Price Performance

Upcoming Events for ADXS

Q1 2024 Ayala Pharmaceuticals Inc Earnings Release

Ayala Pharmaceuticals Inc Annual Shareholders Meeting

Q2 2024 Ayala Pharmaceuticals Inc Earnings Release

Similar to ADXS

Picture of Actavia Life Sciences logo

Actavia Life Sciences

us flag iconPink Sheets on Nasdaq

Picture of Acura Pharmaceuticals logo

Acura Pharmaceuticals

us flag iconPink Sheets on Nasdaq

Picture of Adhera Therapeutics logo

Adhera Therapeutics

us flag iconPink Sheets on Nasdaq

Picture of Ramoil Management logo

Ramoil Management

us flag iconPink Sheets on Nasdaq

Picture of Adynxx logo

Adynxx

us flag iconPink Sheets on Nasdaq

FAQ